The retailing group had been considering a management buy-out.
The pan-European firm stays top of the European leveraged buy-out league.
XTL Pharmaceuticals will be the first Israeli biotechnology firm to list in London.
A record amount was raised from IPOs and secondary offerings in Europe in the first quarter, but the Wall Street Journal reports that investment bankers are increasingly downbeat about prospects in the months to come.